Cyclo Therapeutics, Inc.
cyclotherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 14, 2024. Its latest SEC filing is a 15-12G from Apr 7, 2025.
10-Q for Q3 FY2024, filed Nov 14, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops cyclodextrin-based drug candidates for people with neurodegenerative diseases, including Niemann-Pick Type C and Alzheimer’s, and sells cyclodextrins and related products to pharmaceutical, diagnostics and industrial customers.
10-K for FY2023, filed Mar 18, 2024We are a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases. We…View ↗
We also continue to operate our legacy fine chemical business, consisting of the sale of cyclodextrins and related products to the…View ↗
We currently sell our legacy fine chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical…View ↗
Who Were Their Customers?
Sells legacy fine chemical products directly to pharmaceutical, diagnostics and industrial chemical customers, and to chemical supply distributors. It packages orders at its facility and ships them by common carrier.
10-K for FY2023, filed Mar 18, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 13, 2024
−$8.8MView ↗
- ▲ +85% (Loss)
- vs −$4.8M in Q3 FY2023
-
Mar 26, 2025
Rafael completed its merger with Cyclo Therapeutics
Cyclo became a wholly owned Rafael subsidiary and requested Nasdaq delisting of its stock and warrants.
Sources
8-K, filed Mar 26, 2025
On March 25, 2025, Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), completed the previously announced strategic combination…View ↗
Who Did They Compete With?
Competes with Actelion, Johnson & Johnson, Orphazyme, and IntraBio
10-K for FY2023, filed Mar 18, 2024There is currently no known cure for NPC. Although we face competition in the commercialization of a drug product to treat NPC, we believe…View ↗
Loading...
